Researchers report that a miniaturized semi-perfusion clone screening method and a multi-parameter manufacturability index can improve clone ranking consistency across scales compared with traditional single-metric selection. The work focuses on early process development decisions that affect downstream yield and quality. For cell-therapy and biologics manufacturing teams, the contribution is operational: it targets how candidates are chosen before scale-up, potentially reducing rework and accelerating timelines to produce high-performing clones.